Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

CardioPulm II > Stroke > Flashcards

Stroke Flashcards

(52 cards)

Start Studying
1
Q

Hemorrhagic Stroke: Clinical presentation

A

Worst headache of your life and decreased level of conscientious.

other details,
headache, dizziness, seizures, vomiting, neck rigidity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Hemorrhagic Stroke:
Intracerebral hemorrhage

Secondary Causes

A

uncontrolledbloodpressure ,antithrombotic or thrombolytic

agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hemorrhagic Stroke:

Subarachnoidhemorrhage (SAH)

A

A. Blood enters cerebrospinal fluid

B. Secondary to trauma, rupture of an intracranialaneurysm ,or rupture of an arteriovenous malformation (AVM)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Treatment:
SAH secondary to aneurysm rupture

Associated with increased incidence of delayed cerebral ischemia (DCI)

  • > Occurs between 4 and 21 days after bleed
  • ->Underlying cause of of DCI is vasospasm of cerebral vaculature
A

Nimodipine - used to reduce the compilation owing to DCI

60mg PO every 4 hours X 21 days

ADR: Hypotension

Reduce dosing interval to 30mg PO every 2h (same daily dose) or reduce total daily dose 30mg PO every 4th

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nimodipine (Nimotop): Black Box Warning

A

Do not administer intravenously or parenterally. Will cause Death and Serious ADR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Secondary Prevention: Non-Cardioembolic TIA/Stroke

Artherothrombotic, lacunar, or cryptogenic

What drugs are available and what dose?

A

Aspirin 50-325 PO daily –Cheap *best

ASA 25 mg /Dipyridamole ER (Aggrenox) 200mg PO BID*ok

Clopidogrel 75mg PO daily *last

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Secondary Prevention: Non-Cardioembolic TIA/Stroke

What’s better ASA or ASA/dipyridamole( Aggrenox)?

A

IR dipyridamole failed to show benefit over ASA
-> due to its short half-life and reduced absorption

Aggrenox: HA in 40% of pts. Titrated the does: take 1 pill at night for 2wks, then BID.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Secondary Prevention: Non-Cardioembolic Stroke/TIA

What about long term, Dual anti-playlet therapy?

A

Combo of ASA and Clopidegrel–> is not recommneed

BUT** DAPT is indicated if history of ACS/PCI –> look for stent or intracranial stenosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Secondary Prevention: Cardioembolic Stroke

Use CHADs VASc:

Anticoagulation:

A 
C - Congestive HF
H - HTN
A2 - age >75 (2 points)
D - DM
S2 - PMH of Stroke (opts)
V - vascular disease
A - age 65-74
Sc - sex category ( Female)

0= Choose nothing
1= Choose nothing or ASA or anticoagulation
≥2= Anticoagulation

o No treatment = 0
o ASA 81 -325 mg po daily (usually 81 mg) 
 - Warfarin Goal INR 2-3 --DOC
o Dabigatran 150 mg PO BID
o Rivaroxaban 20 mg PO daily with a mea
o Apixaban 5 mg PO BID
o Edoxaban 60 mg PO Daily
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Primary and Secondary Prevention of Stroke

Hypertension

Drugs and Goals?

A

ACEI + Thiazide or ARB

Goal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Primary and Secondary Prevention of Stroke

Lipid Management: SPARCL (ATV 80 vs. PLB)

Drugs, situation, and goals

A

ATV 40-80 mg daily and ROSVA 20-40 mg daily

Stroke only from artherosclorisis.

Decrease in LDL of at least 50% from baseline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Primary and Secondary Prevention of Stroke

Diabetes mellitus with risk or history of CVD

A

Secondary: ASA 75-162 mg hx of CVD

and

Primary: Aspirin tx (75–162 mg/day) in (1) DM with 10-year risk>10%.

(2) Men 50 yrs of age or women 60 yrs of age who have at least one of the following factors:
(family hx of CVD, HTN, smoking, dyslipidemia, or albuminuria).

Goal Ha1C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Primary and Secondary Prevention of Stroke

Antiplatelet Treatment – Primary Prevention

A

PRIMARY: ASA low dose 81 mg

Men ages 45-79 and Women 55-79

For women the major benefit is stroke prevention

men the primary major benefit is MI prevention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Primary and Secondary Prevention of Stroke:

Obesity/Ethanol Use

Weight management program

Exercise program Healthy diet with increased fruits/ vegetables

Limit alcohol intake

A

Obesity
Goal body mass index 18.5- 24.9 kg/m2

Ethanol
≤ 2 drinks (males)
≤ 1 drink (non-pregnant females)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Primary and Secondary Prevention of Stroke:

Tobacco

A

Bupropion

Nicotine patch/ gum

Varenicline

Nonpharmacologic management`

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acute Ischemic Stroke – Treatment

General Treatment Principles

A
  1. To identify candidates for thrombolytics within 4.5 hours**
  2. Close monitoring of patient for change in metal status
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

General Treatment Interventions for Acute Ischemic Stroke

A

Fluid management: Dehydration and Hypotension

Hyperglycemia: maintain range of 140-180 mg/dL

Hypoglycemia: (38C

Hypertension : mentioned later

DVT/PE prevention: “”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Pharmacologic Treatment of Acute Stroke

Drug/Amistration/BP/other drug??

A

(r-tPA) alteplase- (Activase® )

• Half life 3-8 minutes

  1. Dose: 0.9mg/kg (maximum 90mg)
  2. the first 10% given IV bolus
  3. remaining 90% given by continuous infusion over 1 hour.
  4. BP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

(r-tPA) alteplase- (Activase® )

ADR and Precautions

A

Bleeding, angioedema (tx with ranitidine, diphenhydramine, methylprednisolon)

Develops headache, acute HTN, N/V has worsening neurological exam,
–>discontinue the infusion and obtain emergent CT scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

(r-tPA) alteplase- (Activase® )

Monitoring

A 
Monitoring Parameters: 
BP, Neurologic function, bleeding:
1.q15min X 2hrs
2. Then q30min x 6 hrs
3. Then q60min x 24 hrs
4. qshift
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

NINDS r-tPA Stroke Study Group study:

Excustion Critieria

Study These Flashcards
A
  1. History of previous intracranial hemorrhage
  2. Elevated blood pressure > 185/110
  3. Platelet count 1.7 or PT >15 seconds
  4. Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory tests (such as aPTT, INR, platelet count, and ECT; TT; or appropriate factor Xa activity assays
  5. Blood glucose concentration
22
Q

NINDS r-tPA Stroke Study Group study:

Inclusion Critieria

Study These Flashcards
A
  1. Treatment within 45 minutes
  2. age > 18
  3. ishemic stroke with measurable neuralgic deficit
23
Q

NINDS r-tPA Stroke Study Group study: (3 hour window)

Relative excision criteria

Study These Flashcards
A
  1. minor or rapidly improving stroke symptoms
  2. Pregnacy
  3. MI within 3 months
  4. any trauma or surgery within 14 days
  5. UTI or GI hemorrhage within 21 days
24
Q

ECASS Study:

Additional exclusion criteria if within 3-4.5 hours of onset.

Study These Flashcards
A

! Patient > 80 years
! Those taking oral anticoagulant regardless of their INR
! Baseline NIHSS score > 25
! Those with hx of stroke and diabetes

25
ECASS Study: Expansion of the Time Window for Tx of Acute Ischemic Stroke with r-tPA
patients to test the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke AHA/ASA recommends r-tPA to be given to eligible patients who can be treated in the time period of 3-4.5 hours after stroke
26
NINDS r-tPA Stroke Study Group study:
When inclusion and exclusion of giving rtPA not followed there is increased risk of hemorrhage 15.7 % - 3X rate in other studies The bottom -Stick with the guidelines for giving r-tPA
27
Acute Ischemic Stroke: Antiplatelet agents Aspirin
• 325 mg within 48 hours after stroke onset Wait 24 hours if tPA was used
28
Acute Ischemic Stroke: Antiplatelet agents DAPT
The combination of aspirin and clopidogrel might be considered for initiation within 24 hours of a minor ischemic stroke or TIA and for continuation for 90 days If the patient ends up receiving rtPA, then aspirin 325mg or DAPT can be given after 24 hours
29
Acute Ischemic Stroke: full dose (or treatment dose) anticoagulation with Heparin or LMWH
* Has NOT been shown to decrease disability or mortality | * Has NOT been shown to decrease risk of recurrent stroke • # risk for systemic and CNS hemorrhage
30
Acute Ischemic Stroke: full dose (or treatment dose) anticoagulation with Heparin or LMWH: AFib
Do not use anticoagulation for stroke or A.Fib (UFH/LMWH) For most patients with a stroke or TIA in the setting of AF, it is reasonable to initiate *ORAL* anticoagulation within 14 days after the onset of neurological symptoms
31
Acute Ischemic Stroke: antithrombotic tx for prevention of DVT/PE
Low dose UFH/LMWH should be *restricted for 24 hours* after administration of thrombolytic therapy. low dose has less risk of intracrannial hemorrhage
32
Blood Pressure Management in Acute Stroke
Used to achieve 185/110 so tPA can be used if not using tPA: Use if BP > 220/120 or When patient has the following medical conditions: * Evidence of aortic dissection * Acute myocardial infarction * Pulmonary edema * Hypertensive encephalopathy Goal: reduce systolic BP by 15% during the 1st 24 hrs after stroke onset
33
Blood Pressure Management in Acute Stroke Agents :Indication that patient is eligible for treatment with intravenous rtPA SBP >185mmHg or DBP>110mmHg
Labetalol 10 to 20 mg IV over 1 to 2 minutes, may repeat once or ``` Nicardipine infusion (dihyropyridine CCB) 5 mg/h, titrate up by 2.5 mg/h, , maximum dose 15 mg/h; when desired blood pressure reached. ``` and If BP is not maintained at or below 185/110 mmHg, do NOT administer rtPA
34
Labetalol ADR
Labetalol: Vomiting, scalp tingling, bronchoconstriction, dizziness, nausea, heart block, orthostatic hypotension
35
Nicardipine ADR
Nicardipine: Tachycardia, headache, flushing, local phlebitis
36
Nitroprusside ADR
Nitroprusside: Nausea, vomiting, muscle twitching, sweating, thiocynate and cyanide intoxication
37
Blood Pressure Management in Acute Stroke Management of blood pressure during and after treatment with rtPA or other acute reperfusion intervention – maintain BP at or below 180/105 mmH SBP between 180-230 mmHg or DBP between 105-120 mmHg
Labetalol 10 mg IV followed by an continuous infusion at 2 to 8 mg/min or Nicardipine infusion, 5 mg/h, titrate up to desired effect by increasing 2.5 mg/h every 5 minutes to maximum of 15 mg/h
38
Blood Pressure Management in Acute Stroke Management of blood pressure during and after treatment with rtPA or other acute reperfusion intervention – maintain BP at or below 180/105 mmH DBP > 140 mmHg or if BP not controlled
*Nitroprusside: 0.5mcg/kg/min titrate Q 5min by 0.25mcg/kg/min to max 10mcg/kg/min
39
Stroke: Symptoms
Weakness on one side of the body, inability to speak, loss of vision, vertigo, or falling or Ischemic stroke is not usually painful, but patients may complain of headache, and with hemorrhagic stroke, it can be very severe. ! Teach FAST (Face, Arm, Speech, Time)
40
Tests for Evaluation of Ischemic/hemorrhagic Stroke
CT (  ) of the brain without contrast – most important test to distinguish between hemorrhagic vs. ischemic--Bright White AREA MRI –high resolution; reveals areas of ischemia earlier Electrocardiogram – A.fib detection Carotid Doppler (CD) – to detect stenosis/atherosclerosis extracranial Transcranial Doppler (TCD) – to detect stenosis/atherosclerosis intracranial TTE/TEE
41
Scales for stroke
• National Institutes of Health Stroke Scale (NIHSS) o Evaluates neurologic impairment on a scale of 1 – 42, with higher scores indicating severe neurologic impairment. (usually performed at presentation, 24hrs after admission, and again at discharge). • Modified Rankin Scale (mRS) o A scoring system for measuring disability; scores of 0-1 indicating no to minimal disability; scores of 5-6 indicates severe disability or death. (usually performed at presentation, 24hrs after admission, and again at discharge). • Glasgow Outcome Scale (GOS) o Measure of functional recovery with 1 indicated death and 5 indicating good recovery
42
Complications of Acute Ischemic Stroke
``` Neurological Cerebral edema Hydrocephalus ↑ intracranial pressure (ICP) Hemorrhagic transformation Seizures ``` ``` Medical Aspiration Hypoventilation Pneumonia Myocardial ischemia Cardiac arrhythmias Deep vein thrombosis Pulmonary embolism Urinary tract infection Pressure ulcers Malnutrition ```
43
Cerebral blood flow (CBF): Normal CBF Neurological dysfunction Infarction Penumbra
NormalCBF-50mL/100g braintissue/min-Mean Arterial Pressure 50 to 150mmH Neurologicaldysfunction-~20mL/100g/min - Ishemia ensues Infarction- 8-12mL/100g/min--irreversible damage Penumbra--(~15-20 mL/100g/min; @3-4.5hr): tissue that is ischemic but maintains membrane integrity; potentially salvageable through intervention.
44
Risk Factors: stroke Non- Modifiable
Non- Modifiable ``` Age Sex Non-caucasian Family h/o TIA/ CVA Low birth weight ```
45
Risk Factors: stroke Modifiable
``` HTN: Most important modifiable risk factor Heart disease: A.fib (most important/treatable) & other cardiac diseases Hyperlipidemia Diabetes mellitus Obesity/Physical Inactivity Tobacco use Postmenopausal Hormone Therapy Sickle cell disease Oral contraceptives ```
46
Risk Factors: stroke Potentially Modifiable
Drug & Alcohol abuse Sleep disordered breathing h/o migraine with aura
47
Transient Ischemic Attack (TIA
Transient Ischemic Attack (TIA): Abrupt onset focal neurological deficit that lasts Less than 24 hours usually less than 30min
48
Stroke, Cerebrovascular Accident (CVA Two Types
Ischemic stroke and Intracranial hemorrhagic stroke:
49
Ischemic stroke
87% of all strokes **atherothrombotic**-->The final result is arterial occasion,DECREASING BLOOD FLOW AND CAUSING ISCHEMIA DISTAL TO THE OCCLUSION embolic
50
Intracranial hemorrhagic stroke
**ADRs: warfarin, heparin, ASA, clopidogrel, lytics** cerebral aneurysm hypertension arteriovenous malformation
51
Stoke and Women: it was meant to be.
E. Gender: Stroke is the third-leading cause of death for women. • Some of the impact is explained by the fact that women live longer, and thus the lifetime risk of stroke in those aged 55 to 75 years is higher in women (20%) than men (17%) • Female specific risk factors: Oral contraceptive use, Postmenopausal Hormone therapy, Pregnancy (Preeclampsia / gestational hypertension, gestational diabetes) • Risk Factors That Are Stronger or More Prevalent in Women: A.Fib, HTN, Migraines with aura, HTN, depression, psychosocial stress
52
southeastern US AND stroke
Stroke Belt

CardioPulm II (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions